RIGEL PHARMACEUTICALS, INC. Net Fee Amt
RIGEL PHARMACEUTICALS, INC. (RIGL) had Net Fee Amt of $5.23 thousand as of 2026-08-04, per its S-8 filed 2026-08-04.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-04
- 2026-08-04: Net Fee Amt $5.23K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $5.23K S-8 · filed 2026-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |